Cargando…

Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody

Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the synovial membrane that results in the destruction of bone and cartilage in affected joints. Tocilizumab is a biological agent and an anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6-mediated inflammatory proce...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanagida, Mitsuaki, Kawasaki, Mikiko, Fujishiro, Maki, Miura, Masako, Ikeda, Keigo, Nozawa, Kazuhisa, Kaneko, Hiroshi, Morimoto, Shinji, Takasaki, Yoshinari, Ogawa, Hideoki, Takamori, Kenji, Sekigawa, Iwao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766614/
https://www.ncbi.nlm.nih.gov/pubmed/24058910
http://dx.doi.org/10.1155/2013/607137
_version_ 1782477298136514560
author Yanagida, Mitsuaki
Kawasaki, Mikiko
Fujishiro, Maki
Miura, Masako
Ikeda, Keigo
Nozawa, Kazuhisa
Kaneko, Hiroshi
Morimoto, Shinji
Takasaki, Yoshinari
Ogawa, Hideoki
Takamori, Kenji
Sekigawa, Iwao
author_facet Yanagida, Mitsuaki
Kawasaki, Mikiko
Fujishiro, Maki
Miura, Masako
Ikeda, Keigo
Nozawa, Kazuhisa
Kaneko, Hiroshi
Morimoto, Shinji
Takasaki, Yoshinari
Ogawa, Hideoki
Takamori, Kenji
Sekigawa, Iwao
author_sort Yanagida, Mitsuaki
collection PubMed
description Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the synovial membrane that results in the destruction of bone and cartilage in affected joints. Tocilizumab is a biological agent and an anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6-mediated inflammatory processes in RA patients. In order to identify novel disease-related proteins and candidate biomarkers, we analyzed the changes in the serum proteome profiles of patients with RA who were treated with tocilizumab. Serum samples were collected from the RA patients before and after tocilizumab treatment. Following immunodepletion of major proteins, the proteins were digested and labeled with isobaric tag, iTRAQ reagent. The proteins were identified and quantified using liquid chromatography-tandem mass spectrometry. Among a total of 311 proteins identified, seven were decreased and 16 were increased by tocilizumab treatment. Although some of the proteins are known to be related to RA, several are currently unknown with respect to their relationship to RA and may be involved in the development of this disease. This study is the first to perform a comparative serum proteomic analysis of RA patients treated with tocilizumab. Our results may contribute to the identification of novel disease-related proteins and enhance the understanding of the pathogenesis of RA.
format Online
Article
Text
id pubmed-3766614
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37666142013-09-22 Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody Yanagida, Mitsuaki Kawasaki, Mikiko Fujishiro, Maki Miura, Masako Ikeda, Keigo Nozawa, Kazuhisa Kaneko, Hiroshi Morimoto, Shinji Takasaki, Yoshinari Ogawa, Hideoki Takamori, Kenji Sekigawa, Iwao Biomed Res Int Clinical Study Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the synovial membrane that results in the destruction of bone and cartilage in affected joints. Tocilizumab is a biological agent and an anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6-mediated inflammatory processes in RA patients. In order to identify novel disease-related proteins and candidate biomarkers, we analyzed the changes in the serum proteome profiles of patients with RA who were treated with tocilizumab. Serum samples were collected from the RA patients before and after tocilizumab treatment. Following immunodepletion of major proteins, the proteins were digested and labeled with isobaric tag, iTRAQ reagent. The proteins were identified and quantified using liquid chromatography-tandem mass spectrometry. Among a total of 311 proteins identified, seven were decreased and 16 were increased by tocilizumab treatment. Although some of the proteins are known to be related to RA, several are currently unknown with respect to their relationship to RA and may be involved in the development of this disease. This study is the first to perform a comparative serum proteomic analysis of RA patients treated with tocilizumab. Our results may contribute to the identification of novel disease-related proteins and enhance the understanding of the pathogenesis of RA. Hindawi Publishing Corporation 2013 2013-08-22 /pmc/articles/PMC3766614/ /pubmed/24058910 http://dx.doi.org/10.1155/2013/607137 Text en Copyright © 2013 Mitsuaki Yanagida et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Yanagida, Mitsuaki
Kawasaki, Mikiko
Fujishiro, Maki
Miura, Masako
Ikeda, Keigo
Nozawa, Kazuhisa
Kaneko, Hiroshi
Morimoto, Shinji
Takasaki, Yoshinari
Ogawa, Hideoki
Takamori, Kenji
Sekigawa, Iwao
Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
title Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
title_full Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
title_fullStr Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
title_full_unstemmed Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
title_short Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody
title_sort serum proteome analysis in patients with rheumatoid arthritis receiving therapy with tocilizumab: an anti-interleukin-6 receptor antibody
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766614/
https://www.ncbi.nlm.nih.gov/pubmed/24058910
http://dx.doi.org/10.1155/2013/607137
work_keys_str_mv AT yanagidamitsuaki serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT kawasakimikiko serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT fujishiromaki serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT miuramasako serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT ikedakeigo serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT nozawakazuhisa serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT kanekohiroshi serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT morimotoshinji serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT takasakiyoshinari serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT ogawahideoki serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT takamorikenji serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody
AT sekigawaiwao serumproteomeanalysisinpatientswithrheumatoidarthritisreceivingtherapywithtocilizumabanantiinterleukin6receptorantibody